Navigation Links
Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
Date:3/29/2008

91 percent, p=0.04).

"The reduction in risk seen in patients in this analysis treated with prasugrel over patients treated with clopidogrel is encouraging for high-risk patients with acute coronary syndrome being managed with PCI," said J. Anthony Ware, M.D., Lilly vice president for cardiovascular/acute care.

About the TRITON-TIMI 38 stent analysis

TRITON-TIMI 38 was a Phase III, multi-center, randomized, double blind, parallel group, head-to-head clinical trial comparing the effects of prasugrel vs. clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI). PCI is a procedure to open blockages in heart arteries including the use of coronary stenting. The study enrolled 13,608 patients at 707 trial sites in 30 countries.

The primary endpoint of the study was to compare the effects of prasugrel to clopidogrel on the composite incidence of cardiovascular death, non-fatal heart attack, or non-fatal stroke during a median period of 14.5 months following PCI. Key secondary objectives included rehospitalization for a cardiac ischemic event; the need for additional procedures to restore blood flow (urgent target vessel revascularization) at 30 days; and stent thrombosis. Key safety endpoints included non-CABG major, life threatening and minor bleeding as well as the overall safety and tolerability of prasugrel.

Patients were randomly assigned to one of two treatment groups and given a loading dose of either prasugrel 60 mg or the approved loading dose of clopidogrel 300 mg anytime between randomization and one hour after the completion of the PCI procedure, followed by a daily maintenance dose of either prasugrel 10 mg or clopidogrel 75 mg. All patients also received a daily low dose of aspirin.

Subjects enrolled in TRITON were included in the stent analysis if they received at least one coronary stent at randomization and were further subdivided based on the types of stents received.
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
2. St. Jude Study Offers New Hope for Children With Kidney Tumors Deemed Inoperable
3. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
6. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
7. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
8. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
9. New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women
10. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
11. Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Moms are ready to live the ... and their kids, according to the results of the ... Go Mobile for Moms, the latest installment in BabyCenter,s ... 1 pregnancy and parenting web and mobile destination worldwide, ... moms surveyed say they can,t think of a reason ...
(Date:10/22/2014)... 2014 AVACEN Medical announced today that its ... OTC clearance by the U.S. Food and Drug Administration. ... over the Internet for: the temporary relief of ... strains and sprains . Logo - ... $2495) is a sophisticated medical device incorporating over 3,000 ...
(Date:10/22/2014)... 2014  CryoLife, Inc. (NYSE: CRY ), ... on cardiac and vascular surgery, announced today that ... Officer, has been elected to the Company,s Board of ... G. Anderson , Executive Chairman of CryoLife, stated, "Since joining ... an excellent leader who is well positioned to maximize ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3
... , , , PARSIPPANY, N.J., Jan. 11 ... pharmaceutical industry your survival depends on not only what you ... Pharma market research is key. Whoever has the right ... U.S. pharmaceutical industry is the largest (and growing) market in ...
... , ... Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP ... clinical trial of a prototype formulation of its proprietary delayed-release cysteamine ... M.D., Professor of Pediatrics at the University of California, San Diego, ...
Cached Medicine Technology:Elite Pharma Insiders to Reveal Key Survival Strategies for Pharmaceutical Industry in 2010 2Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 2Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 3Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 4Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 5Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 6Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 7
(Date:10/22/2014)... (HealthDay News) -- The United States is now ... nations of West Africa land at one of ... with the virus. In a statement released ... 94 percent of air passengers from Guinea, Liberia ... these five airports -- New York City,s Kennedy ...
(Date:10/22/2014)... Pass, OR (PRWEB) October 22, 2014 ... Southern California’s fresh water supply runs dangerously low, Southern ... change. Southern Oregon’s rivers, despite the lowest mountain snow ... even in late summer and early autumn.* That was ... authors of the new book “Hiking Southern Oregon,” during ...
(Date:10/22/2014)... Viejo, CA (PRWEB) October 22, 2014 ... Jay Cormier, Sr. Vice President of Sales, will be ... the upcoming Meetings Technology Expo on October 28, at ... also be hosting a booth as well as a ... how Lintelus Meeting can create a more engaging event ...
(Date:10/22/2014)... 2014 (HealthDay News) -- Two sisters in high school ... Ilina and Medha Krishen use electronic stethoscopes, which ... trouble in breathing patterns or heartbeats. Ilina, a ... wanted to find a way to detect early lung ... an electronic stethoscope, Ilina recorded one breath cycle each ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay News) -- ... NBC News in Liberia has cleared the virus from ... Medical Center in Omaha, where he had been treated for the ... confirmed by the U.S. Centers for Disease Control and Prevention found ... NBC News reported Tuesday night. "Recovering from Ebola is ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... , ST. LOUIS, Sept. 15 KV ... 2009, the Company received an action by written consent of ... stockholders of certain amendments to the Company,s By-Laws (the "Proposed ... Proposed Amendments, is attached as Exhibit 99.1 to ...
... , , , ... through retirement, the number of people affected by Alzheimer,s is likely to ... Day, Retirement Living TV (RLTV), the only network dedicated to adults 50+, ... 21 at 8PM (EDT) . , , To ...
... of these patients die before discharge, study finds , TUESDAY, Sept. ... while hospitalized, those who require dialysis are not at increased risk ... they are more likely to need dialysis on a ... the authors of a new study published in the Sept. 16 ...
... a big reason why, researchers say , TUESDAY, Sept. ... in the hospital are much less likely to survive than ... disparity appears to result from the hospital in which black ... well, the researchers said. , "We know that survival after ...
... , WASHINGTON, Sept. 15 According to ... majority of liberals oppose extending taxpayer-funded healthcare to illegal immigrants. ... plan and agree with the President,s handling of healthcare reform, ... to illegal aliens and result in increased costs. The ...
... , , Caregivers say it,s ... in a bid to woo SEIU-UHW members , , ... , , SAN FRANCISCO, Sept. 15 Home ... that it failed in its attempt to force a new union election. The ...
Cached Medicine News:Health News:KV Pharmaceutical Receives Stockholder Action by Written Consent 2Health News:KV Pharmaceutical Receives Stockholder Action by Written Consent 3Health News:KV Pharmaceutical Receives Stockholder Action by Written Consent 4Health News:KV Pharmaceutical Receives Stockholder Action by Written Consent 5Health News:KV Pharmaceutical Receives Stockholder Action by Written Consent 6Health News:Retirement Living TV Premieres 'Not Fade Away' September 21st to Honor World Alzheimer's Day 2Health News:Retirement Living TV Premieres 'Not Fade Away' September 21st to Honor World Alzheimer's Day 3Health News:Kidney Injury While Hospitalized May Lead to Future Dialysis 2Health News:Blacks Fare Worse After Cardiac Arrest 2Health News:Blacks Fare Worse After Cardiac Arrest 3Health News:Poll: Liberals Oppose Healthcare for Illegal Aliens 2Health News:San Francisco Home Care Workers Demand that Former Union Officials Come Clean 2Health News:San Francisco Home Care Workers Demand that Former Union Officials Come Clean 3
Albarran double-horn bridge for use with sheaths from 20-25 Fr and designed for accurate articulation of flexible devices....
Only SurLok combines precise control, enhanced basket and grasper strength, and the added security of a unique wire-locking mechanism. You can feel the difference. The SurLok flat-wire and grasper ha...
Used for ureteral dilation and stone manipulation in the ureter. Supplied sterile in peel-open packages. Intended for one-time use....
... in the urinary tract. The N-Force basket is ... shape of Delta Wire creates a three wire ... superior mass of the Delta Wire combined with ... a basket with increased radial force which permits ...
Medicine Products: